Kornimate/medical-research-clean huggingface dataset:
outcome of laparoscopic total mesorectal excision versus open technique in management of rectal carcimoma

Conditions: Rectal Carcinoma

Summary: colorectal cancer is the second leading cause of death in the west, and rectal cancer accounts for about 25% of colon cancers low anterior resection has been the mainstay of rectal cancer surgery in low rectal cancer since the 1970s. although the best efforts of experienced surgeons, the local recurrence rate is 3 to 33% in conventional surgery, while total mesorectal excision (tme) results indicate a recurrence rate of less than 10% the evolution of the concept of tme which was first revealed by heald.in 1982 made a major shift in the treatment strategies (rodriguez-luna et al,2015). the concept of tme was the most important event in surgery for rectal cancer in the last two decades, because even without a curative approach, the local recurrence decreased to 6 to 12%, and 5-year survival improved by 53-87% tme described clear definitions of distal resection margin (drm), circumferential resection margin (crm), and least number of harvested lymph nodes, so oncological outcomes improved, locoregional recurrence and survival rates also influenced . laparoscopic total mesorectal excision (ltme) may be associated with less blood loss, earlier recovery, and lower morbidity. identification of the small nerves and vessels became easiear because of laparoscopic magnified view of pelvis and thus prevents these injuries (sajid et al, 2019). also, minimal surgical trauma will reduce the immunologic response and preserves postoperative immunologic defenses. this may lead to low rate of infections as well as low local recurrences and distant metastases in addition to, tissue handling with less manipulation, 'may reduces the spread of cancer cells tme in obese males with low and anterior rectal tumors is technically challenging especially post neoadjuvant chemoradiotherapy due to distortion of the anatomical planes (ng et al, 2014). in these patients, it is difficult to obtain a proper view of the dissection plane, in open technique which threatens the integrity of tme and carries the risk of positive margins, which is related to higher rates of local recurrence ltme is a widely used approach for rectal cancers; although conversion rate varies from 1.2 to 17%, and it is higher if bmi is equal to or more than 30


Eligibility criteria:
inclusion criteria: * all patients with pathologically confirmed rectal carcinoma involving middle or lower third rectum and operable by mri and ct scan criteria. * both sexes will be included. * age: ranging from 20 to 70 years. exclusion criteria: * patients with stage iv. * recurrent rectal cancers. * combined malignancy. * patients admitted due to emergency situations (acute large bowel obstruction, abdominal abscess, or rectal perforation and hemorrhage). * patients with contraindication for laparoscopic surgery. * unfit patients (asa score \> ii).
short-term embolization using gelatin particles for flow modulation during y90 radioembolization

Conditions: Liver Cancer (Primary and Metastatic)

Summary: the segway trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of flow diversion to protect non-tumorous liver function using short-acting gelatin sponge particles during yttrium-90 radioembolization of liver cancer.

short-acting gelatin sponge particles will be used during radioembolization to protect normal liver tissue in patients with liver cancer whose treatment field encompasses a substantial portion of non-tumorous liver tissue. recanalization of the embolized hepatic artery will be assessed by angiography within 30 minutes following the procedure. suppression of y90 microsphere delivery to the protected, non-tumorous liver tissue will be evaluated using y90 pet-ct imaging, by comparing the protected regions to non-protected, non-tumorous regions within the perfused area. enhanced tumor uptake of y90 microspheres will be quantified using the tumor-to-normal liver ratio (tnr), calculated by comparing pre-procedure spect-ct with post-procedure pet-ct data. finally, preservation of liver function in protected tissue relative to unprotected tissue will be assessed six months post-procedure using signal intensity ratios on hepatobiliary phase images obtained from gadoxetic acid-enhanced mri.

Eligibility criteria:
inclusion criteria: 1. adults aged 19 years or older 2. patients diagnosed with primary or metastatic liver cancer based on histological and/or radiological findings 3. patients determined, following medical, surgical, or multidisciplinary evaluation, to be best treated by radioembolization 4. patients with no history of local treatments (e.g., ablation, chemoembolization) to the same hepatic lobe within the past year 5. child-pugh class a 6. eastern cooperative oncology group (ecog) performance status of 2 or lower 7. patients whose treatment area, as determined by planning angiography, includes at least two liver segments 8. patients for whom normal liver tissue constitutes 50% or more of the treatment volume exclusion criteria: 1. liver cancer with vascular invasion 2. for primary liver cancer, patients who have been diagnosed with a malignancy other than the primary liver cancer within 2 years prior to study enrollment 3. patients who have undergone biliary-enteric anastomosis 4. patients with an estimated lung dose of 30 gy or higher on pre-procedure 99mtc-maa imaging 5. patients with a known contraindication to gelatin use
effect of annona muricata leaves on colorectal cancer patients and colorectal cancer cells

Conditions: Colorectal Cancer

Summary: annona muricata l., include the leaves, is found to contain biologically active annonaceous acetogenins and plant polyphenols that are important components of human diet and a number of them are considered to have chemopreventive and therapeutic properties against cancer. to confirm previous findings in in vitro, animal study and traditionally use, a human, ex vivo and in vitro studies were conducted to evaluate the effects of consecutive ingestion of a. muricata leaves extract for eight weeks.

colorectal cancer patients were randomly assigned to receive either a. muricata leaves extract or placebo. dietary intakes and anthropometry were assessed with food record every two weeks. blood parameters, nutritional status, quality of life, fecal butyrate level, and systemic inflammation of patient were assessed at the beginning and the end of study.

Eligibility criteria:
inclusion criteria: * patients with colorectal carcinoma * have undergone standard therapy * satisfactory haematological or biochemical functions * karnofsky performance status of ≥ 60% * willing not to take probiotic supplement during study period exclusion criteria: * uncontrolled hypertension * serious heart, kidney, liver endocrine or neurologic/psychiatric diseases * physical and mental disability that renders them unable to verbally communicate * history of recent cancers * pregnant, lactating, or not using adequate contraception * patient on other investigational drug

Keywords: patients after surgery
evaluating the need for pneumatic compression devices

Conditions: Osteoarthritis

Summary: for patients undergoing total hip and knee arthroplasty, does the use of aspirin alone compared to using aspirin along with a mobile compression device provide equivocal results for preventing deep vein thrombosis (dvt) and pulmonary embolism (pe) after total joint arthroplasty? the investigator will evaluate the prevention of dvt/pe after total hip and knee arthroplasty will be evaluated to see if there is a decreased risk of bleeding while continuing to prevent thromboembolic disease. the equivalency of using the mobile compression devices with aspirin compared to aspirin alone in patients undergoing total hip and knee arthroplasty will be evaluated. a previous study has shown that patient compliance with the pneumatic compression device is less than 80%.

the research question is: does the use of aspirin alone compared to using aspirin along with a mobile compression device provide equivocal results for preventing deep vein thrombosis (dvt) and pulmonary embolism (pe) after total joint arthroplasty? participants were randomized to either receive aspirin and mobile pneumatic compression devices or aspirin alone as outpatient dvt prophylaxis as their standard of care after primary total hip and total knee arthroplasty. participants randomized to the compression device group were asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an aspirin (325mg once a day), per standard of care. participants randomized to aspirin alone took 325 mg per day. participant usage information from active care +s.f.t. mobile devices was collected. the information was recorded at the participant's first follow up visit occurring between 7-21 days post-surgery. all of the participants were asked to keep a checklist indicating aspirin intake compliance each day, which was returned at their first follow up visit. participants randomized to mobile pneumatic compression device and aspirin (325 mg) were asked to complete a satisfaction questionnaire about the compression device at their first follow up visit. participants received a phone call from a member of the research team approximately 90 days post-op. the call was necessary to assess if any participants have been diagnosed with dvt at another hospital.

Eligibility criteria:
inclusion criteria: 1. all patients, 18+ years of age, scheduled at wvu medicine center for joint replacement for a history and physical visit to undergo a total hip or knee surgery. 2. primary replacements and revisions. 3. weight bearing as tolerated postoperatively. exclusion criteria: 1. history of dvt/pe 2. history of hypercoagulable disorder 3. currently on other blood thinning medication with the exception of aspirin (plavix, coumadin, xarelto, pradaxa, lovenox, heparin, other factor xa inhibitors). 4. patients less than 18 years of age.
specific respiratory infections as triggers of acute medical events

Conditions: Influenza, Human; Respiratory Syncytial Virus Infections; Parainfluenza; Rhinovirus; Adenovirus; Human Metapneumovirus Pneumonia; Cardiovascular Diseases

Summary: this study will investigate whether there is a population-level association between circulating respiratory viruses and nhs hospital admissions for acute vascular events using data from national infection surveillance and hospital episode statistics.

we will conduct a time series study correlating anonymised population level data on all samples from nhs laboratories testing positive for six common respiratory viruses with admissions to nhs hospitals in england for a range of cardiac and vascular outcomes over the time period 01/01/2004 to 31/12/2014. this will involve generating poisson regression models controlling for factors such as seasonal and long-term trends, environmental temperature and humidity. this study is funded by an academy of medical sciences starter grant for clinical lecturers.

Eligibility criteria:
inclusion criteria: * any individual with a record of an eligible outcome (icd-10 coded hospitalisation for myocardial infarction or stroke) within the study period aged 45+ years * any individual with a record of an eligible exposure (laboratory-confirmed respiratory virus) within the study period at any age exclusion criteria: * outcome events occurring in people aged \<45 years
fludarabine and cytarabine as continuous infusion plus g-csf priming for elderly patients with resistant aml

Conditions: Acute Myeloid Leukemia

Summary: * to determine the feasibility of fludarabine and cytarabine as continuous infusion plus granulocyte-colony stimulating factor priming for elderly patients with resistant acute myeloid leukemia other than acute promyelocytic leukemia * the feasibility will be evaluated in terms of toxicities, complete remission rate, duration of complete remission, disease-free survival, and overall survival.

* a second course of induction chemotherapy can be given to the patient when a partial remission but less than a complete remission is achieved after the first course. at least 4 weeks should be apart between start of the first course and start of the second course. * g-csf (lenograstim) 250 g/day will begin to be administered after the confirmation of hypocellular bone marrow with blasts less than 5% on day 14 or later until absolute neutrophil counts are 1,000/l or more. * for the patients who achieve a complete remission, consolidation therapy will be given as follows: * two more cycles of the same chemotherapy will be given to the patients who achieve a complete remission after single induction course. allogeneic or autologous hematopoietic cell transplantation could be also considered. * in patients who relapse after allogeneic hematopoietic cell transplantation, donor leukocyte infusion will be done without consolidation chemotherapy. * in patients who had extramedullary relapse(s), local radiotherapy can be given to the relapse site(s).

Eligibility criteria:
inclusion criteria: * failure to achieve cr after initial induction chemotherapy * any relapse, regardless of the frequency and time of relapse from first cr * relapse after hematopoietic cell transplantation, allogeneic or autologous. * multiple relapses, extramedullary relapse(s) exclusion criteria: * inadequate hepatic,renal,cardiac function * psychiatric disorder or mental deficiency * cns involvement of leukemic blasts

Keywords: aml
the effect of severe weight loss and protein intake on bone

Conditions: Weight Loss

Summary: the purpose of this study is to learn whether the amount of dietary protein can influence bone health during the weight loss after weight loss surgery.

it is unclear whether the amount of protein in the diet during caloric restriction influences bone density. this information is important for determining optimal nutrient requirements during weight loss. this study will examine usual and higher dietary protein intake during severe weight loss following weight loss surgery on bone turnover, mass and quality in women, with the hypothesis that higher protein intake will reduce bone turnover and loss, and/or prevent the changes in bone quality associated with severe weight loss in women ages 18 to 70 years. participants will be randomly assigned to one of 2 groups: a) weight loss with recommended level of protein intake, or b) weight loss with higher protein intake. a dietitian will provide instructions for a reduced calorie, well balanced diet throughout the 12-month study using a nutrition-education behavior- modification program. participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month. in addition they will be asked to take a daily vitamin/mineral supplement and, depending on their usual food intake, they may be asked to take a calcium tablet to meet the recommended intake throughout the study period. bone, mineral, protein and lipid markers, and hormones that influence bones will be measured. these measurements will provide information about body composition (fat, muscle mass, and bone mineral density).

Eligibility criteria:
inclusion criteria: * women ages 18 to 70 who are undergoing gastric bypass surgery * must live in the geographic vicinity of rutgers university exclusion criteria: * currently on any medication known to influence calcium or bone metabolism, including hrt, or with evidence of diseases known to influence calcium metabolism (i.e. metabolic bone disease, hyperparathyroidism, untreated thyroid disease, significant immune, hepatic, or renal disease, significant cardiac disease \[i.e., heart attack or stroke in the past 6 months., abnormal ekg\], active malignancy or cancer therapy within the past year) * history of kidney stones * weight gain or weight loss (5% of body wt) within 3 months prior to recruitment * participation in other investigational studies during the 12-month study period * usually have a very high or low intake of calcium (more than 1500 or less than 500 mg per day)

Keywords: bone mass calcium absorption bone quality fracture risk
toe amputations in patients with diabetes

Conditions: Diabetic Foot; Infections; Amputation

Summary: this study is a randomized controlled trial (rct) to evaluate outcome after toe amputation due to diabetic foot infection. aim of this rct is to evaluate wound healing and functional outcome based, whether wound is closed or left open. as a part of this study, emerging technology of thermal imaging is evaluated as a possible tool to predict complication after amputation.

patients with diabetes undergoing toe amputation due to infection, are recruited for this study. based on randomization, wound is either closed or left open during the amputation procedure. if primary closure is not possible (e.g. deep abscess) and patient is randomized to closed group, delayed closure is performed when feasible. patients are followed up in outpatient clinic 3 month after amputation. primary outcome is wound healing that is evaluated during follow ups in the outpatient clinic. functional outcome is evaluated with prom questionnaires preoperatively and during the follow up.

Eligibility criteria:
inclusion criteria: * toe amputation due to diabetic foot infection exclusion criteria: * deep foot infection * sepsis * no clinical infection (amputation due to trauma, deformity or uninfected necrosis)

Keywords: diabetic foot infection amputation
a 1-year multi-center, prospective, cohort study in patients with chronic obstructive pulmonary disease treated with long-acting bronchodilator

Conditions: COPD

Summary: this multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed copd patients who require adding daily maintenance therapy in real world. the study planned to enroll 550 patients in indacaterol group and 9450 patients in non- indacaterol group, a total of 10,000 patients. enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. finally a total of 2229 patients were analyzed in full analysis set. a total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. hence a total of 2229 patients enrolled successfully.


Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent * physician-diagnosis of copd * copd patients requiring long-acting bronchodilator treatment * patients with spirometry available at baseline exclusion criteria: * patients who have a diagnosis of asthma. * patients who had been hospitalized for a copd exacerbation in the 4 weeks prior to visit 1. * current clinical diagnosis of other chronic respiratory illnesses * concurrent participation in a clinical trial or use of an investigational drug. * active malignancy or history of malignancy of any organ system * pregnant or nursing (lactating) women * women of child-bearing potential with no contraception other protocol-defined inclusion/exclusion criteria may apply.

Keywords: copd chronic obstructive pulmonary disease (copd), chronic obstructive lung disease (cold), chronic obstructive airway disease (coad), cronchitis, emphysema
palonosetron versus ramosetron for the prevention of postoperative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: ramosetron and palonosetron are more recently developed 5-hydroxytryptamine type 3 receptor antagonists and this randomized double blind study was designed to compare efficacy of ramosetron and palonosetron to prevent postoperative nausea and vomiting. investigator hypothesized that palonosetron would have stronger and longer lasting antiemetic effect compared with ramosetron and evaluated the patients for the first 48 hours after surgery.


Eligibility criteria:
inclusion criteria: * asa physical status 1 or 2 * elective gynaecological laparoscopic surgery of ≥ 1h duration exclusion criteria: * anti-emetics, steroids, or psychoactive medications within 24 h of study initiation * vomiting or retching in the 24 h preceding surgery * cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry * ongoing vomiting from gastrointestinal disease

Keywords: antiemetics ramosetron palonosetron ponv(postoperative nausea and vomiting)
safety study of parathyroid hormone in patients needing additional stem cell mobilization.

Conditions: Lymphoma; Multiple Myeloma; Acute Myelogenous Leukemia

Summary: the purpose of this study is to determine the safety of parathyroid hormone in combination with g-csf when used as a stem cell mobilization regimen for patients who fail to mobilize sufficient progenitor stem cells after one or two attempts.

patients will start treatment within 21 days of the determination of inadequate mobilization. pth treatment will be given in 4 cohorts: 40 mcg, 60 mcg, 80 mcg, and 10 mcg. pth will be given on day 1 and continue until stem cell collections are complete or a maximum of 20 days. g-csf 10 mcg/kg will be given on days 10-14 and continue until stem cell collections are complete. patients with inadequate cd34+ cells on day 14 will meet off study criteria and not continue with pth/g-csf.

Eligibility criteria:
inclusion criteria: * disease status: nhl or hd refractory to chemotherapy, relapsed, o high risk first remission; multiple myeloma; aml in second or subsequent remission or in first remission with adverse cytogenetics or antecedent hematologic disorder. * failed one or two mobilization attempts. * ecog performance status of 0, 1, or 2. exclusion criteria: * cardiac disease: symptomatic congestive heart failure, angina pectoris or uncontrolled hypertension * pulmonary disease: severe chronic obstructive lung disease, or symptomatic restrictive lung disease. * renal disease: serum creatinine \> 2 mg/dl * hepatic disease: sgot or sgpt \> 3x normal; serum bilirubin \> 2.0 mg/dl that is not due to gilbert's syndrome or hemolysis * calcium \> 10.5 * phosphate \< 1.6 * uncontrolled infection * pregnancy or breast feeding mother

Keywords: mobilization stem cell parathyroid hormone
duragen® secure post marketing clinical follow-up (pmcf)

Conditions: Dura Mater Nick Cut or Tear; Surgery

Summary: the purpose of this study is to gather information about post-market performance of duragen secure.the aim of this post market clinical follow-up (pmcf) is to obtain post market clinical data to evaluate the presence of unintended residual risks associated with the use of duragen secure that were not anticipated or identified in the animal studies, bench studies or clinical evaluation report.


Eligibility criteria:
inclusion criteria: * patient who have undergone a neurosurgical procedure where duragen® secure has been implanted exclusion criteria: * patient who does not agree to allow collection of his/her medical data